Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.

The Dutch firm expects the financing to advance its novel asset Microlyse into a potentially pivotal study for a rare blood disorder.

Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, but BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings. 

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.